Cargando…
IL-21 and Sjögren's syndrome
Treatment of Sjögren's syndrome is almost entirely symptomatic. A lack of true understanding of the underlying immunological pathology of the disease prevents directed therapy. Interleukin-21 (IL-21) is elevated in the serum of patients with this disease and is expressed by the lymphocytes infi...
Autor principal: | Scofield, R Hal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334639/ https://www.ncbi.nlm.nih.gov/pubmed/22226370 http://dx.doi.org/10.1186/ar3518 |
Ejemplares similares
-
Clinical Characteristics and Outcome of Primary Sjogren’s Syndrome: A
Large Asian Indian Cohort
por: Sandhya, Pulukool, et al.
Publicado: (2015) -
Association between Secondary and Primary Sjögren's Syndrome in a Large Collection of Lupus Families
por: Aggarwal, Rachna, et al.
Publicado: (2015) -
Do we need new autoantibodies in lupus?
por: Scofield, R Hal
Publicado: (2010) -
Sjogren’s Syndrome: Recent Updates
por: Skarlis, Charalampos, et al.
Publicado: (2022) -
Stratifying primary Sjögren’s syndrome: killers in the balance?
por: Bowman, Simon J., et al.
Publicado: (2015)